Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · Mkt capMarket cap $107.65B · View financials
Snapshot Sep 4, 4:00 PM ET
FY 2026 · Mkt cap
Decision snapshot: GSK stock price vs FLO: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at FLO's multiple
Needs FLO P/E.
Implied fair value · at GSK's multiple
Needs GSK P/E.
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Multiple premium
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: GSK FY 2025 (ended Dec 31, 2025) · FLO FY 2026 (ended Jan 3, 2026). Fiscal years are not aligned.
Trendline
Six fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 71% equity / 29% debt · EV / Revenue 3.71x · EV / EBITDA 19.25x
Capital structure 38% equity / 62% debt · EV / Revenue 0.66x · EV / EBITDA 7.93x
GSK carries the larger enterprise value at $163.76B against $3.47B; FLO trades on the lower EV / Revenue multiple (0.66x vs 3.71x); FLO on the lower EV / EBITDA (7.93x vs 19.25x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
GSK plc · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
FLOWERS FOODS INC · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
—
1.65x
Net debt / EBITDA
Leverage against operating earnings
6.59x
4.90x
Cash and equivalents
Liquid reserves on the balance sheet
$3.40B
$12.10M
Total debt
Interest-bearing obligations outstanding
$44.87B
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
PFIZER INC
GSK vs PFE
ELI LILLY & Co
GSK vs LLY
BRISTOL MYERS SQUIBB CO
GSK vs BMY
JOHNSON & JOHNSON
GSK vs JNJ
AbbVie Inc.
GSK vs ABBV
AMGEN INC
GSK vs AMGN
Gentherm Inc
GSK vs THRM
Post Holdings, Inc.
GSK vs POST
J M SMUCKER Co
GSK vs SJM
Zoetis Inc.
GSK vs ZTS
CONAGRA BRANDS INC.
GSK vs CAG
COCA COLA CO
GSK vs KO
$2.15B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.
